Chardan Capital Issues Optimistic Forecast for TNYA Earnings

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) – Equities researchers at Chardan Capital boosted their FY2025 EPS estimates for shares of Tenaya Therapeutics in a research note issued to investors on Tuesday, November 11th. Chardan Capital analyst Y. Livshits now forecasts that the company will post earnings of ($0.61) per share for the year, up from their prior forecast of ($0.68). Chardan Capital currently has a “Buy” rating and a $9.00 price target on the stock. The consensus estimate for Tenaya Therapeutics’ current full-year earnings is ($1.35) per share.

Other equities research analysts have also recently issued research reports about the company. Wall Street Zen raised Tenaya Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 9th. HC Wainwright reaffirmed a “buy” rating and issued a $5.00 price objective on shares of Tenaya Therapeutics in a research note on Tuesday, September 2nd. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Tenaya Therapeutics in a report on Wednesday, October 8th. Four research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $6.25.

Tenaya Therapeutics Price Performance

Shares of Tenaya Therapeutics stock opened at $1.37 on Friday. Tenaya Therapeutics has a one year low of $0.36 and a one year high of $4.01. The firm has a market capitalization of $228.11 million, a price-to-earnings ratio of -1.76 and a beta of 3.13. The business has a 50-day simple moving average of $1.55 and a 200 day simple moving average of $0.99.

Tenaya Therapeutics (NASDAQ:TNYA) last posted its quarterly earnings results on Monday, November 10th. The company reported ($0.12) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.03.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. CWM LLC grew its stake in Tenaya Therapeutics by 14,231.7% in the 1st quarter. CWM LLC now owns 71,945 shares of the company’s stock valued at $41,000 after purchasing an additional 71,443 shares during the period. Virtu Financial LLC boosted its stake in Tenaya Therapeutics by 29.4% in the first quarter. Virtu Financial LLC now owns 135,502 shares of the company’s stock valued at $77,000 after acquiring an additional 30,790 shares during the last quarter. Nuveen LLC bought a new position in shares of Tenaya Therapeutics during the 1st quarter valued at approximately $129,000. Callan Family Office LLC purchased a new stake in shares of Tenaya Therapeutics during the 1st quarter worth approximately $50,000. Finally, Comerica Bank bought a new stake in shares of Tenaya Therapeutics in the 1st quarter worth approximately $50,000. Hedge funds and other institutional investors own 90.54% of the company’s stock.

Tenaya Therapeutics Company Profile

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.